tirzepatide cvot results An Observational Study of Cardiovascular Outcomes of vs Glucagon-Like Peptide-1 Receptor Agonists Tirzepatide CV Safety Comparable to

Tirzepatide is the first approved dual GIP/GLP-1 receptor agonist, engineered from the native GIP peptide backbone with structural modifications enabling potent activation of both incretin receptors

This suggests that orforglipron can serve as a "step-down" oral maintenance therapy after achieving target weight loss with more potent injectables

While Tirzepatide is a highly effective weight-loss tool, there are certain things you should avoid while on this medication

This is particularly relevant for patients transitioning from poorly controlled diabetes to improved glycaemic stability

Semaglutide (Wegovy): Up to 14.9% average weight loss

Individual variation means your personal results could differ from trial averages